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Abstract
Background: Co-infections of hepatitis B and C viruses are frequent with HIV due to shared routes of transmission.
In most of the tertiary care health settings, HIV reactive patients are routinely tested for HBsAg and anti-HCV
antibodies to rule out these co-infections. However, using the routine serological markers one can only detect
active HBV infection while the occult HBV infection may be missed. There is insufficient data from India on HIV-HBV
co-infection and even scarce on occult HBV infection in this group.
Methods: We estimated the burden of HBV infection in patients who were tested positive for HIV at a tertiary care
centre in north India. We also attempted to determine the prevalence and clinical characteristics of occult HBV infection
among these treatment-naïve patients and compare their demographic features with other HIV patients. During a
period of 6 years between January 2002 to December 2007, 837 HIV positive patients (631 males and 206 females (M: F
:: 3.06:1) were tested for serological markers of HBV (HBsAg) and HCV (anti-HCV antibodies) infections in our laboratory.
For comparison 1000 apparently healthy, HIV-negative organ donors were also included in the study. Data on
demographics, sexual behaviour, medical history, laboratory tests including the serum ALT and CD4 count of these
patients were recorded. A sub-group of 53 HBsAg negative samples from HIV positive patients were assessed for anti-
HBs, anti-HBc total (IgG+IgM) and HBV-DNA using a highly sensitive qualitative PCR and analysed retrospectively.
Results: Overall, 7.28% of HIV positive patients showed presence of HBsAg as compared to 1.4% in the HIV
negative control group. The prevalence of HBsAg was higher (8.55%) in males than females (3.39%). The study
revealed that occult HBV infection with detectable HBV-DNA was prevalent in 24.5% of patients positive for anti-
HBc antibodies; being 45.5% in HBsAg negative patients. Most importantly the occult infection was seen in 20.7%
patients who were positive for anti-HBs antibodies. However, in none of the seronegative patient HBV-DNA was
detected. Five of the nine HBV-DNA positive (55.6%) patients showed raised alanine aminotransferase levels and
66.7% had CD4
+ T cell counts below 200 cells/cumm.
Conclusions: High prevalence of HIV-HBV co-infection was found in our patients. A sizeable number of co-infected
patients remain undiagnosed, if only conventional serological markers are used. Presence of anti-HBs antibodies
was not a reliable surrogate marker to rule out occult HBV infection. The most reliable method to diagnose occult
HBV co-infection in HIV seropositive patients is the detection of HBV-DNA.
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Human immunodeficiency virus (HIV) establishes a
chronic and latent infection in the body that induces
extensive damage to the immune system through virus-
related as well as indirect pathogenic mechanisms [1].
HIV infected individuals show not only a quantitative
depletion of CD4+ T cells but also an overall immune
dysregulation. Hepatitis B virus (HBV) is a frequent co-
contaminant with HIV, mainly because both share com-
mon modes of transmission. Whether the presence of
one facilitates the sexual transmission of the other is a
matter under investigation, but both are easily trans-
mitted through infected blood, unsafe injections and
equipments. Over the years, much evidence has accu-
mulated that co-infection with HIV significantly modi-
fies the natural history of HBV infection [2,3]. Highly
active antiretroviral therapy (HAART) is well known to
prolong the survival of HIV-infected individuals which
allows a longer time for cirrhosis to develop in HBV co-
infected patients. Therefore, HAART increases the rela-
tive proportion of deaths attributable to liver disease in
these patients. HAART may also have a major impact
on HBV co-infection because of restoration of specific
and non-specific immune responses and decrease of
aberrant activation and dysregulation of the immune
system [4]. Withdrawal or development of resistance to
drugs that are dually active against both HIV and HBV
has been associated with reactivation of HBV infection
and with flares of liver enzyme elevations and hepatic
decompensation in patients with advanced liver disease
[5,6].
At our institute all HIV reactive patients are also
screened for hepatitis B surface antigen (HBsAg), if
treating physician has any suspicion of co-infection.
However, not all hepatitis B virus co-infections are
symptomatic and even routine serological markers can
miss the diagnosis of HBV disease. Those patients who
turn out to be positive for HBV-DNA in the absence of
serum HBsAg are known as occult hepatitis B virus
(HBV) infections [7]. Occult HBV infection is charac-
terised by long lasting persistence of HBV-DNA in
serum, and/or hepatic tissues of individuals negative for
serum HBsAg. The presence of antibodies to HBV core
antigen (anti-HBc-IgM) is now recognized as a better
indicator of progressing occult HBV infection. But,
recent estimates suggest that up to 20% of individuals
with occult HBV could be negative even for anti-HBc
antibodies or any other serological indicator of exposure
to HBV [7]. Some studies also show that the detection
of naturally acquired antibodies to HBsAg (anti-HBs)
does not exclude the existence of occult infection [8],
indicating that diagnosis of occult HBV co-infection is a
challenging task for laboratory physicians.
True prevalence and clinical significance of occult
HBV infections is scarcely reported in the literature.
Occult HBV has been implicated in the transmission of
the HBV via transfusion of blood and blood products
[9,10] and transplanted solid organs [11] leading to
hepatitis in recipients. Reactivation of occult infection
has also been reported in hematologic malignancies
[12], and immunosuppressed states [13] with reconstitu-
tion of immune surveillance associated with activation
of virus and cytotoxic T-cell mediated hepatitis. How-
ever, the prevalence of occult HBV infection in HIV-
infected persons is more so controversial because of the
lack of standardization of diagnostic methods and fewer
prospective studies. Studies have reported rates of occult
HBV markedly varying from as low as nil to as high as
89.5% [14-17] in these patients. However, there are only
a few reports of occult HBV infection, as such from
India and even scarce in HIV seropositive patients. In
this study, we estimated the burden of HBV in patients
who tested positive for HIV at a tertiary care centre in
north India. We also attempted to determine the preva-
lence and clinical characteristics of occult HBV among
HIV-infected, treatment- naïve patients.
Methods
Study population
The study was carried out in the Clinical Microbiology
Division, Department of Laboratory Medicine at the All
India Institute of Medical Sciences (AIIMS). At this
referral institute patients suspected with HIV associated
illnesses are seen in the medicine out-patient clinics.
Here they are counselled by a social worker and
informed consent is taken for testing. As a routine, our
laboratory follows the World Health Organization
(WHO) testing strategies for HIV test followed by post-
test counselling of the patients and this is documented.
As an investigative protocol at the institute, all con-
firmed HIV positive patients are screened for Hepatitis
B (HBsAg) and C viruses (anti-HCV antibodies) as a
part of their pre-ART work-up beside other tests. A ret-
rospective analysis was performed on data collected
from January 2002 to December 2007 in the laboratory.
Laboratory analysis
Serum samples from 837 proven HIV seropositive
patients (WHO testing strategy III, as mentioned above)
were collected, labelled with a laboratory identification
serial number and stored at -20°C in separate aliquots
for further testing upto 10 years or till the storage space
is available. From these samples one aliquot was tested
for HBsAg and for anti-HCV antibodies using enzyme
linked immunosorbent assay kits (bio Merieux, France).
All serum samples were tested in duplicate.
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but HBsAg negative patients, we selected 53 serum sam-
ples randomly, for reasons of feasibility and availability
of reagents and quantity of samples. These were tested
for occult HBV infection viz. for anti-HBs antibodies
(bio Merieux,F r a n c e ) ,a n t iH B ct o t a l( I g G +I g M ;biokit,
Spain) and a qualitative PCR for HBV DNA (SORPO-
line™ HBV end-point PCR kit) was also done. This PCR
kit has a reported sensitivity of 10-30 copies of HBV.
Risk factors and transaminase levels weer ascertained at
the time of sample collection. Data on demographics,
sexual behaviour, medical history, other laboratory tests
including., serum ALT and CD4+ count were also ana-
lysed from the records. All tests were performed in
accordance with the institutional ethical guidelines at
that time. Data of 1000 age and sex matched HIV-nega-
tive healthy organ donors was also analysed to compare
the prevalence of hepatitis markers. These organ donors
are screened with due consent for viral markers as a
routine work-up for their family members requiring
organ transplantation, as described earlier [18].
Statistical analysis
Comparison of proportions among different groups
and characteristics was done using Fisher’se x a c tt e s t .
p < 0.05 was taken as significant.
Results
A retrospective analysis was performed on laboratory
data from 837 HIV sero-reactive patients who were
tested in our laboratory from January 2002 to December
2007. Among the study subjects, there were 631 males
and 206 females (M: F - 3.06:1). These patients aged
between 1-73 years (median 32 years). Overall, HBsAg
positivity (HBV co-infection) was seen in 61 (7.28%)
HIV positive patients. This rate was highly significant (p
< 0.0001) when compared to 1.4% in the control group
which comprised of age and sex matched HIV-negative
healthy persons. Further, out of the 61 serologically
(HBsAg positive) reactive subjects for HIV and HBV co-
infection; 54 were males and 7 female. Our patients
were in the age range of 14-69 years (median 36 years),
but the HBsAg positivity rate was significantly higher in
males (8.55%) as compared to 3.39% in female patients
(p = 0.0129). Majority (635 of 837) of the HIV positive
patients were aged between 21-40 years. This trend was
similar in HIV-HBV co-infected patients also (table 1).
Among the 53 HBsAg negative samples tested for
occult HBV infection, 41 (77.4%) were males and 12
(22.6%) females. The age group of these patients ranged
from 21-59 years (median 32 years). The patients
belonged to different risk groups, but the heterosexual
risk group was the most predominant. None of these
patients gave history of vaccination against HBV.
Serological markers of HBV exposure (other than
HBsAg, i.e. either anti-HBs or anti-HBc antibody positiv-
ity) were seen in 45.3% (24 out of 53) patients. While in
29 patients no marker was detected (table 2). Among
these 53 patients, 20.7% (11) showed anti-HBs antibodies
and 35.8% (19) anti-HBc (total) antibodies. There was no
statistical difference in the prevalence of these markers in
two genders; being 46.3% in males and 41.7% in females
(table 2). Of the various risk factors for occult HBV infec-
tion, male gender combined with low CD4
+ counts below
200 cells/cumm and raised alanine aminotransferase
levels (>40 IU/L) were most significant (table 3).
HCV co-infection was seen in only 5 (9.4%) of the 53
HBsAg negative patients. This rate was only marginally
lower (6.2%) in 61 HBsAg positive pool. Among the HIV-
HCV co-infected patients, positivity for anti-HBs/anti-HBc
was seen in 80% samples as compared to 41.7% in HCV
negative samples (p = 0.163). Tuberculosis (TB) is a com-
mon infection in Indian HIV positive patients; hence we
compared the presence of these serological markers of
occult HBV infection in HIV-TB co-infected and unin-
fected patients. We found that presence of either of the
HBV markers was seen in 35.2% of TB positive patients
and in 50% of TB uninfected patients. This difference was
statistically insignificant. Anti-HBc alone (in absence of
anti-HBs) as a marker of occult infection was seen in
11.3% of samples tested and was associated with lower
CD4
+ levels below 200 cells/cumm in 84.6% patients (p =
0.032) as compared to higher CD4
+ levels (table 3). None
Table 1 Comparative distribution of HIV positive patients
by age and gender divided into two groups on the basis
of presence or absence of HBsAg
HBs-Ag positive (n = 61)
Age Groups (in years) & no.(%)
Sex <20 21-30 31-40 >41 Total
Male 1 (1.6) 17 (27.9) 21 (34.4) 15 (24.6) 54 (88.5)
Female 1 (1.6) 2 (3.3) 2 (3.3) 2 (3.3) 7 (11.5)
Total 2 (3.2) 19 (31.2) 23 (37.7) 17 (27.9) 61 (100)
HBsAg Negative (n = 776)
Sex Age Groups (in years) & no. (%)
<20 21-30 31-40 >41 Total
Male 29 (3.7) 191 (24.6) 238 (30.7) 119 (15.3) 577 (74.4)
Female 12 (1.5) 97 (12.5) 67 (8.6) 23 (3) 199 (25.6)
Total 41 (5.2) 288 (37.1) 305 (39.3) 142 (18.3) 776 (100)
Total HIV positive patients (n = 837)
Sex Age Groups (in years) & no. (%)
<20 21-30 31-40 >41 Total
Male 30 (3.5) 208 (24.8) 69 (8.2) 25 (3) 631 (75.4)
Female 13 (1.5) 99 (11.8) 69 (8.2) 25 (3) 206 (24.6)
Total 43 (5.1) 307 (36.7) 328 (39.2) 159 (19) 837 (100)
Note the number in parenthesis is percentage distribution in each group.
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tion with anti-HBc positivity.
HBV-DNA was positive in 45.3% (24/53) samples
which were negative for HBsAg but positive for other
HBV serological marker. As mentioned above, none of
29 patients who were negative for all HBV seromarkers
was positive for HBV-DNA. In patients who were posi-
tive only for anti-HBc antibodies, we found a 24.5% (13/
53) prevalence rate of occult HBV infection (HBV-DNA
positive). However, the most significant finding of this
study was that HBV-DNA was detected in 20.7% (11/53)
patients in whom circulating anti-HBs antibodies were
detectable. Of the HBV-DNA positives 55.6% (5 of 9)
patients showed raised alanine aminotransferase levels
while 66.7% (6 of 9) had a CD4
+ T cell counts below
200 cells/cu mm. The prevalence rates of HBV-DNA
were comparable in both males (36.8%) and females
(40%). The demographic and laboratory characteristics
of HBV-DNA positive and negative patients were signifi-
cantly indifferent (table 3).
Discussion
Co-infection of HIV significantly modifies the natural
history of HBV infection. Before availability of HAART
it was associated with a higher chronicity rate of acute
hepatitis B, higher levels of HBV replication, a lower
rate of spontaneous loss of HBV antigens and a high
rate of reactivation [2-4]. However, even after wide-
spread institution of HAART, studies have shown
increased number of deaths attributed to liver disease
possibly due to prolonged survival and time for devel-
opment of cirrhosis. Reports of flares of necro-inflam-
matory activity in liver are also documented due to
restoration of adaptive HBV specific immune response
and innate non-specific immune responses [4]. The
treatment of HBV in HIV co-infected patients is com-
plex because the drug(s) used are associated with
drug-resistance, cross-resistance, hepatotoxicity and
unresponsiveness. Another major concern is reactiva-
tion of HBV replication after withdrawal of dually
active antiviral drugs leading to emergence of resistant
strains.
Our study findings indicate that HIV-infected
patients are at a higher risk of HBV co-infection in
our set-up, as illustrated by the high prevalence of
HBsAg (7.28%) in HIV positive patients in comparison
to HIV negative patients (1.4%). Male patients were
f o u n dm o r el i k e l yt ob ec o - i n f e c t e dw i t hH B Va s
Table 2 Characteristics and positivity rate of other HBV serological markers in HBsAg-negative HIV-seropositive











No HBV marker detected
(%)
Overall 53 24 (45.3) 19 (35.8) 11 (20.7) 13 (24.5) 5 (9.4) 29 (54.7)
Sex
Male 41 19 (46.3) 16 (39.0) 8 (19.5) 11 (26.8) 3 (7.3) 22 (53.6)
Female 12 5 (41.7) 3 (25) 3 (25) 2 (16.7) 2 (16.7) 7 (58.3)
Risk factors
a
Heterosexual 46 20 (43.5) 16 (34.8) 8 (17.4) 12 (26.1) 4 (8.7) 26 (56.6)
Transfusion 3 2 (66.7) 1 (33.3) 2 (66.7) 0 1 (33.3) 1 (33.3)
IVDU 2 2 (100) 2 (100) 1 (50) 1 (50) 0 0
CD4 cell counts
≤ 200 35 15 (42.8) 12 (34.3) 4 (11.4) 11 (31.4) 3 (8.5) 20 (57.1)
201-499 12 7 (58.3) 5 (41.7) 6 (50) 1 (8.3) 2 (16.7) 5 (41.6)
≥ 500 6 2 (33.3) 2 (33.3) 1 (16.7) 1 (16.7) 0 4 (66.7)
ALT levels
Normal 30 14 (46.6) 11 (36.6) 8 (26.6) 6 (20) 4 (13.3) 16 (53.3)
Raised
b 23 10 (43.4) 8 (34.7) 3 (13.0) 7 (30.4) 1 (4.3) 13 (56.5)
Other co-infections
HCV pos
c 5 4 (80) 3 (60) 2 (40) 2 (40) 1 (20) 1 (20)
TB pos
d 17 6 (35.3) 5 (29.4) 3 (17.6) 3 (17.6) 1 (5.9) 11 (64.7)
Note: n, total no. tested; HCV, hepatitis C virus; TB, Mycobacterium tuberculosis; ALT, alanine aminotransferase; IVDU, injection drug use. Determined by Fisher’s
exact test for proportions
a In 2 patients no risk factor could be ascertained.
b Defined as serum ALT levels >40 IU/L
c Determined by anti-HCV IgM antibodies
d Diagnosis of tuberculosis was based on clinical suspicion, chest X-ray findings and sputum mycobacteriology
Gupta and Singh BMC Infectious Diseases 2010, 10:53
http://www.biomedcentral.com/1471-2334/10/53
Page 4 of 7compared to females (table. 1). This trend can be
explained on the basis of higher rate of sexual promis-
cuity and other exposure risks in males. The majority
of HIV-HBV co-infections were seen in the sexually
active population indicating a common mode of trans-
mission to these viruses, as has been previously docu-
mented [19]. Our study also shows a very high
persistence of HBV genome (overall 37.5%) even in
those patients who are HBsAg negative. The study
further shows that like HBsAg other serological mar-
kers were also of lesser value to rule out the occult
infection of HBV which is supported by the data that
occult HBV infection was frequent in those who were
positive for anti-HBc antibodies and also those who
had significant levels of anti-HBs antibodies in their
serum. Presence of Anti-HBc antibodies alone was also
found associated with low CD4
+ cell counts (less than
200), even though these patients were treatment naive.
Interestingly presence of naturally acquired antibodies
to HBsAg (anti-HBs) did not exclude the existence of
occult infection.
The clinical relevance of occult HBV infection in
humans is not limited to blood banks but it is a still
ongoing process. HBV particles may persist for decades
after self-limited acute hepatitis and clinical recovery
[20]. Thus, though occult infection alone may not have
clinical consequences but may become injurious only
when the virus is reactivated after immunosuppression
[12,13]. A number of explanations for the persistence of
HBV-DNA in HBsAg negative samples have been pro-
posed, including the presence of HBV-DNA at a low
copy number [21], genetic variations in the S gene [22]
and the presence of immune complexes in which
HBsAg may be hidden [23]. Many epidemiologic and
molecular studies indicate that persistent HBV infection
may have a critical role in the development of hepato-
cellular carcinoma in HBsAg-negative patients. Occult
HBV infection and its potential oncogenicity are tradi-
tionally considered a consequence of the capacity of the
virus to be integrated into the host genome, although
many observations now show that free episomal HBV
genomes may persist in the liver cells during occult
infection. It may induce mild long lasting necroinflam-
mation [20] and may progress to cirrhosis and hepato-
cellular carcinoma [24]. Studies have also shown that
mutations in the hepatitis B X gene (HBx) protein mod-
ify the functioning of p53, a tumor suppressor gene
[25]. It is still unclear if there is an altered prevalence of
such mutations in occult HBV infections or if coinfec-
tion with HIV could play a catalytic role.
Though reactivation of HBV infection (in the
absence of HBsAg) has been described anecdotally in
HIV-infected patients following severe immune deple-
tion and/or lamivudine withdrawal, yet the true preva-
lence and clinical impact of occult HBV infection in
HIV- infected subjects is controversial due to lack of
methodological standardisation and fewer prospective
s t u d i e s .T h ea v a i l a b l ed a t ao np r e v a l e n c eo fo c c u l t
HBV are wildly divergent and inadequate. In fact, the
p u b l i s h e dp r e v a l e n c er a t e sr a n g ef r o m0 %t o8 9 % ,w i t h
a considerable number of other studies reporting
results between these two extremes [26]. One basis for
difference could be the difference in methodologies
adopted by various workers and the number of sam-
ples tested. One recent study which tested a prospec-
tive cohort of 909 HIV positive patients for occult
HBV showed a prevalence of 1.3% [17], but the sera
were pooled in this study which makes it incomparable
to ours. However, there is no study from Indian sub-
continent to compare our results.
HBV-DNA detection has made significant impact on
the management of these patients. According to treat-
ment guidelines for HIV co-infected individuals, it is
advocated that HBsAg positive patients should be
treated in presence of elevated HBV-DNA, raised
Table 3 Characteristics and HBV-DNA positivity in HBsAg
negative HIV positive patients with or without the
presence of other marker of HBV infection












Male 19 0.6 7 (77.8) 12 (80) 1.0
Female 5 2 (22.2) 3 (20)
Risk factors
Heterosexual 20 0.3 8 (88.9) 12 (80) 1.0
Transfusion 2 1 (11.1) 1 (6.7)
IVDU 2 0 2 (13.3)
CD4 cell counts
≤ 200 15 0.03 6 (66.7) 9 (60) 1.0
>200 9 3 (33.3) 6 (40)
ALT levels
Raised
b 9 0.73 5 (55.6) 7 (46.7) 1.0
Other infections
HCV pos
c 4 1.0 1 (11.1) 3 (20) 1.0
TB pos
d 6 1.0 3 (33.3) 3 (20) 0.63
Note: Figures indicate number and percentage (in parenthesis) of patients
unless indicated otherwise. n = total no. tested; HCV, hepatitis C virus; TB,
tuberculosis; ALT, alanine aminotransferase; IVDU, injection drug use
a Determined by Fisher’s exact test for proportions
b Defined as serum ALT levels >40 IU/L
c Determined by anti-HCV IgM antibodies
d Diagnosis of tuberculosis was based on clinical suspicion, chest X-ray
findings and sputum mycobacteriology
* In none of the remaining 29 patients, who were negative for all HBV
seromarkers, HBV DNA was detected.
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But, as yet no clear guidelines have been established
for occult HBV co-infection in HIV positive patients.
Moreover, the issue needs to be addressed whether to
offer HBV vaccine to HBsAg negative HIV positive
patients harbouring occult HBV infection. This study
even though had some limitations, clearly indicates
that routinely used serological markers of HBV infec-
tion do not rule out occult and ongoing Hepatitis B
virus infection and emphasizes application of molecu-
lar methods for the detection of occult HBV infection
in these patients. Some blood banks around the world
have now routinely started nucleic acid testing (NAT)
to ensure safe blood transfusion practices. However,
this practice needs to be extended at every blood bank
and specially when managing the HIV positive
patients.
Limitation of The study
A major limitation in our study was the small sample
s i z ea n dt h a ti tw a sas i n g l et i m ep o i n tt e s t i n gw i t h o u t
any follow-up. The sample size of the studied patients
was small even though we have a large pool of patients
due to cost constraints. The HBV-DNA estimation
along with all serological marker costs us approximately
US 100 per patients. We are in process of getting funds
to test all our patients to assess the prevalence of occult
HBV infection in all HIV positive patients. We also had
limitation of not doing multivariate analysis of the data.
Since it was a cross-sectional study we could not com-
ment on the clinical significance of occult HBV in HIV
patients included in our study. Lastly, since ours is a ter-
tiary care referral centre, hence a patient selection bias
cannot be completely ruled out.
Conclusion
A sizeable number of HIV-HBV co-infected patients
remain undiagnosed, if only conventional serological
markers for HBV are used. The presence of anti-HBs
antibodies is also an unreliable surrogate marker to rule
out occult HBV infection. Though the most reliable
method to diagnose occult HBV co-infection in HIV
seropositive patients remains the detection of HBV
DNA, it would not be practical yet to recommend this
highly sensitive molecular assay for each and every
patient in resource limited countries.
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